📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales. (2017)

First Author: McCarthy EM

Attributed to: MAximizing Sle ThERapeutic PotentiaL by Application of Novel and Stratified approaches (MASTERPLANS) funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1093/rheumatology/kex044

PubMed Identifier: 28431104

Publication URI: http://europepmc.org/abstract/MED/28431104

Type: Journal Article/Review

Volume: 56

Parent Publication: Rheumatology (Oxford, England)

Issue: 6

ISSN: 1462-0324